Literature DB >> 15990222

Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.

Daniel S Metzinger1, Douglas D Taylor, Cicek Gercel-Taylor.   

Abstract

Treatment failures result from resistance to chemotherapy in ovarian cancer. The effect of cisplatin and paclitaxel treatments on chemosensitivity was studied in ovarian cancer cells developed from a patient with stage IIIC disease. Cells (UL-3A, UL-3B) that recovered from cisplatin (Cis) and paclitaxel (Tax) treatments showed higher levels of p53, mdr-1 and chemoresistance than untreated controls. EC50 values of Cis and Tax for UL-3A clones were 7.2-34.6, average 20.9 microg/ml, while UL-3B clones ranged from 11.8-252.0 microg/ml, with a mean value of 73.2 microg/ml for Cis, and 260.0-4400.0 nM (mean 2555.0 nM) for Tax. Selection pressures during treatment may contribute to drug resistance.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15990222     DOI： 10.1016/j.canlet.2005.05.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  8 in total

1.  2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase.

Authors:  Wei-Ling Chang; Chih-Shiang Chang; Po-Cheng Chiang; Yunn-Fang Ho; Ju-Fang Liu; Kai-Wei Chang; Jih-Hwa Guh
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Ceramide-Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations.

Authors:  Sachin K Khiste; Zhijun Liu; Kartik R Roy; Mohammad B Uddin; Salman B Hosain; Xin Gu; Sami Nazzal; Ronald A Hill; Yong-Yu Liu
Journal:  Mol Cancer Ther       Date:  2019-10-23       Impact factor: 6.261

3.  MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.

Authors:  Yang Zhang; Liying Geng; Geoffrey Talmon; Jing Wang
Journal:  J Biol Chem       Date:  2015-01-23       Impact factor: 5.157

Review 4.  Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.

Authors:  Javed Ahmad; Sohail Akhter; Nigel H Greig; Mohammad Amjad Kamal; Patrick Midoux; Chantal Pichon
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 5.  Nanopreparations to overcome multidrug resistance in cancer.

Authors:  Niravkumar R Patel; Bhushan S Pattni; Abraham H Abouzeid; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2013-08-23       Impact factor: 15.470

6.  Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp.

Authors:  Minzhi Zhao; Chunni Lei; Yadong Yang; Xiangli Bu; Huailei Ma; He Gong; Juan Liu; Xiangdong Fang; Zhiyuan Hu; Qiaojun Fang
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

7.  lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer.

Authors:  Qing Li; Juan Zhang; Juan Zhou; Binglie Yang; Pingping Liu; Lei Cao; Lei Jing; Hua Liu
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

8.  Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells.

Authors:  Jolanta Szenajch; Alicja Szabelska-Beręsewicz; Aleksandra Świercz; Joanna Zyprych-Walczak; Idzi Siatkowski; Michał Góralski; Agnieszka Synowiec; Luiza Handschuh
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.